Literature DB >> 19274491

Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers.

Stephan L Haas1, Monica Abbatista, Joachim Brade, Manfred V Singer, Ulrich Böcker.   

Abstract

BACKGROUND: An imbalance of cytokines is believed to contribute to the immunopathogenesis of inflammatory bowel diseases (IBD). Serum cytokine levels may correlate with disease activity and acute phase reactivity. AIM: To determine the correlation of systemic interleukin-18 (IL-18) levels with disease activity and other markers of inflammation using a crosssectional pilot study in outpatients with IBD.
METHODS: Peripheral venous blood was obtained from 84 patients with Crohn's disease (CD) and from 46 patients with ulcerative colitis (UC). Serum levels of C-reactive protein (CRP), IL-8, IFN-gamma, IL-12p70 and IL-18 were assessed by ELISA. Disease activity was expressed by the Crohn's Disease Activity Index (CDAI) and the Clinical Activity Index (CAI), respectively. Statistical analysis comprised correlation coefficients and linear regression analysis.
RESULTS: In CD IL-18 and other cytokine concentrations, CRP levels, leukocyte and platelet counts did not correlate with the CDAI. However, IL-18 as well as IL-8 and platelets positively correlated with CRP levels (p <0.001), while IFN-gamma and IL-12p70 did not. In contrast, in UC only the CAI and CRP levels showed a significant positive correlation. COMCLUSIONS: In CD IL-18 lacks significant correlation with the CDAI, as do serum acute phase protein and other cytokine markers of inflammation. As opposed to UC, IL-18 and IL-8 may, however, serve as indicators of acute phase reactivity in CD and should be explored in a larger study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19274491     DOI: smw-12482

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  9 in total

1.  Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets.

Authors:  Bertalan Mesko; Szilard Poliska; Andrea Szegedi; Zoltan Szekanecz; Karoly Palatka; Maria Papp; Laszlo Nagy
Journal:  BMC Med Genomics       Date:  2010-05-05       Impact factor: 3.063

Review 2.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

3.  Usefulness of assessing circulating levels of resistin, ghrelin, and IL-18 in alcoholic acute pancreatitis.

Authors:  Piotr Daniel; Bartosz Leśniowski; Anna Jasińska; Mirosława Pietruczuk; Ewa Małecka-Panas
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

4.  C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.

Authors:  Ryota Iwasa; Akihiro Yamada; Koji Sono; Ryuichi Furukawa; Ken Takeuchi; Yasuo Suzuki
Journal:  BMC Gastroenterol       Date:  2015-08-14       Impact factor: 3.067

5.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06

Review 6.  Interleukin-18 and IL-18 binding protein.

Authors:  Charles A Dinarello; Daniela Novick; Soohyun Kim; Gilles Kaplanski
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

7.  Roseburia intestinalis‑derived flagellin ameliorates colitis by targeting miR‑223‑3p‑mediated activation of NLRP3 inflammasome and pyroptosis.

Authors:  Xing Wu; Shiyu Pan; Weiwei Luo; Zhaohua Shen; Xiangrui Meng; Mengwei Xiao; Bei Tan; Kai Nie; Ting Tong; Xiaoyan Wang
Journal:  Mol Med Rep       Date:  2020-07-23       Impact factor: 2.952

8.  Sustained suppression of IL-18 by employing a vaccine ameliorates intestinal inflammation in TNBS-induced murine colitis.

Authors:  Qingdong Guan; Richard Warrington; Sem Moreno; Gefei Qing; Carolyn Weiss; Zhikang Peng
Journal:  Future Sci OA       Date:  2019-07-30

9.  Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases.

Authors:  Lorenzo Bertani; Gian Paolo Caviglia; Luca Antonioli; Rinaldo Pellicano; Sharmila Fagoonee; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Corrado Blandizzi; Francesco Costa; Davide Giuseppe Ribaldone
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.